Concateno joins on-the-spot testing market with £64m Cozart buy
This article was originally published in Clinica
Executive Summary
Drug and alcohol testing specialist Concateno is set to pay £64.4m ($129m) in cash for fellow UK company Cozart in a bid to gain on-the-spot testing capabilities. The deal will see Concateno pay 57.5p per Cozart share - a 41% premium over Cozart's closing share price on September 3.